Navigation Links
Iso-osmolar X-ray dye falters in PCI study
Date:4/1/2008

CHICAGO, Ill. (April 1, 2008) - A new study has found that an x-ray dye intended to reduce stress on the kidneys did not prevent renal injury during percutaneous coronary intervention (PCI) in patients who already had compromised kidney function. In addition, it made no difference in the need for dialysis or in the length of hospital stay, according to the Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty (CONTRAST) study.

The CONTRAST study is being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

Some earlier studies have shown that iodixanol (Visipaque) reduces the risk of kidney damage when moderate doses of x-ray dye, or contrast medium, are used, mainly during diagnostic angiography. This is the first randomized trial to look exclusively at PCI, which involves far higher doses of contrast medium.

Heart disease is a serious health problem for patients with chronic renal failureand places them in a special bind. Depending on the severity of kidney dysfunction, the risk of suffering a heart attack or another type of cardiovascular event is estimated to be as much as four-fold higher than in patients without chronic renal failure.

"Patients with chronic renal insufficiency have a high need of coronary procedures; however, these procedures involve the use of contrast medium, which may lead to contrast-induced nephropathy, or further kidney damage," said Rainer Wessely, MD, PhD, an associate professor of medicine at Deutsches Herzzentrum, Technische Universitaet, Munich, Germany. "In addition, since chronic renal failure is associated with a higher incidence of diffuse and complex coronary artery disease, invasive procedures often require the use of elevated contrast volumes."

In fact, although the risk of contrast-induced nephropathy (CIN) in patients with normal kidney function is very low (far below 1 percent), it is as high as 20 percent to 30 percent in patients with chronic kidney disease. Iodixanol, a contrast agent that has approximately the same osmolarity as blood, was designed to reduce the stress on the kidneys and significantly cut the risk of CIN when compared to contrast medium with a higher osmolarity.

For the study, Dr. Wessely and his colleagues recruited 324 patients with at least mild renal insufficiency (serum creatinine 1.5 mg/dL or an estimated glomerular filtration rate < 60 mL/min/1.73m2) who needed PCI for coronary artery disease. Patients were randomly assigned to receive either iso-osmolar iodixanol (290 mOsm/L) or low-osmolar iomeprol (618 mOsm/L) contrast medium during PCI. All patients received intravenous hydration with a saline solution both before and after the procedure.

Researchers found that the proportion of patients who developed CIN was similar in the two groups (22.2 percent in the iodixanol group vs. 27.7 percent in the iomeprol group, p=0.25). Rates of severe CIN were not significantly different (6.2 percent vs. 3.7 percent, respectively, p=0.30). The need for dialysis was low in both groups (1.9 percent vs. 0.6 percent, p=0.31). Patients remained in the hospital an average of 6.3 days and 6.5 days, respectively (p=0.59).

Clinical outcomes were similar as well. After 90 days of follow-up, there was no significant difference in individual and combined rates of heart attack, death and repeat coronary procedure.

Dr. Wessely will present the results of the "The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty (CONTRAST) study on Tuesday, April 1 at 11:45 a.m. CDT in the Grand Ballroom, S100.


'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. SMRT Architects and Engineers Selected to Design New $115M Digital X-Ray Manufacturing Facility for GE Healthcare
2. Varian Medical Systems Acquires Pan-Pacific Enterprises for Marketing, Sales and Distribution of X-Ray Imaging Products in China
3. Orthopaedic Clinic of Daytona Beach Chooses IDC for Transition to Digital X-ray
4. Aribex Unveils New Handheld Intraoral X-ray System - NOMAD Pro
5. Penn study finds pro-death proteins required to regulate healthy immune function
6. New study shows promise in reducing surgical risks associated with surgical bleeding
7. Study, meta-analysis examine factors associated with death from heatstroke
8. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
9. Study says COPD testing is not measuring up
10. Preclinical study suggests organ-transplant drug may aid in lupus fight
11. Ability to cope with stress can increase good cholesterol in older white men, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: